Disclosures for "Results of a Phase III, Randomized, Placebo-controlled Crossover Trial with N-acetyl-L-leucine for Niemann-Pick Disease Type C "
-
Dr. Bremova-Ertl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Intrabio. The institution of Dr. Bremova-Ertl has received research support from InnoSuisse. Dr. Bremova-Ertl has received research support from Baasch-Medicus.
-
Ms. Fields has received personal compensation for serving as an employee of IntraBio. Ms. Fields has stock in IntraBio. Ms. Fields has received intellectual property interests from a discovery or technology relating to health care.
-
Prof. Factor has stock in IntraBio. An immediate family member of Prof. Factor has stock in IntraBio. Prof. Factor has a non-compensated relationship as a Chairman with IntraBio that is relevant to AAN interests or activities. An immediate family member of Prof. Factor has a non-compensated relationship as a Director with IntraBio that is relevant to AAN interests or activities.
-
Dr. Martakis has nothing to disclose.
-
Dr. Strupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertify. Dr. Strupp has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for IntraBio. Dr. Strupp has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Strupp has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers. Dr. Strupp has stock in IntraBio.